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elisabeth Perez-ruiz1,2,3,4,5, Luna Minute1,2, Itziar Otano1,2, Maite Alvarez1,2, Maria Carmen Ochoa1,2,6, Virginia Belsue1,2,  
Carlos de Andrea2,7, Maria esperanza rodriguez-ruiz1,3, Jose Luis Perez-Gracia2,3,6, Ivan Marquez-rodas6,8,  
Casilda Llacer9, Martina Alvarez5,10,11, Vanesa de Luque5,10, Carmen Molina1,2, Alvaro teijeira1,2,6, Pedro Berraondo1,2,6,13* & 
Ignacio Melero1,2,3,6,12,13*
Combined PD-1 and CTLA-4-targeted immunotherapy with 
nivolumab and ipilimumab is effective against melanoma, renal 
cell carcinoma and non-small-cell lung cancer1–3. However, this 
comes at the cost of frequent, serious immune-related adverse 
events, necessitating a reduction in the recommended dose of 
ipilimumab that is given to patients4. In mice, co-treatment 
with surrogate anti-PD-1 and anti-CTLA-4 monoclonal 
antibodies is effective in transplantable cancer models, but also 
exacerbates autoimmune colitis. Here we show that treating 
mice with clinically available TNF inhibitors concomitantly 
with combined CTLA-4 and PD-1 immunotherapy ameliorates 
colitis and, in addition, improves anti-tumour efficacy. Notably, 
TNF is upregulated in the intestine of patients suffering from 
colitis after dual ipilimumab and nivolumab treatment. We 
created a model in which Rag2−/−Il2rg−/− mice were adoptively 
transferred with human peripheral blood mononuclear cells, 
causing graft-versus-host disease that was further exacerbated 
by ipilimumab and nivolumab treatment. When human colon 
cancer cells were xenografted into these mice, prophylactic 
blockade of human TNF improved colitis and hepatitis in 
xenografted mice, and moreover, immunotherapeutic control 
of xenografted tumours was retained. Our results provide 
clinically feasible strategies to dissociate efficacy and toxicity 
in the use of combined immune checkpoint blockade for cancer 
immunotherapy.
Treatment with the anti-PD-1 monoclonal antibody nivolumab in 
combination with the anti-CTLA-4 monoclonal antibody ipilimumab 
produces synergistic immunotherapeutic effects in patients who are 
affected by a variety of cancers1–4. Following convincing evidence on 
the efficacy of combined CTLA-4 and PD-1 blockade in mouse models 
of cancer5–8, a phase I dose-escalation clinical trial was conducted in 
patients with metastatic cutaneous melanoma. This resulted in clinical 
responses that were frequent, strong and sustained over time4; 
however, over 40% of patients suffered serious immune-related adverse 
events, necessitating a reduction in the dose of ipilimumab in the 
recommended combination regimens for phase II trials9. In the phase 
I trial, one cohort of six patients with melanoma was given a biweekly 
dose of 3 mg kg−1 nivolumab together with 3 mg kg−1 ipilimumab; all 
six experienced marked clinical responses but the treatment had to be 
stopped because of dose-limiting toxicity4. Moreover, evidence from a 
randomized phase III trial of patients with melanoma indicated that a 
dose of 10 mg kg−1 of ipilimumab alone every three weeks resulted in 
longer overall survival than a regimen with 3 mg kg−1 of ipilimumab 
alone10.
Immune-related adverse events that result from therapy with check-
point inhibitors are usually satisfactorily treated by discontinuing the 
use of the therapeutic agents and beginning a course of steroids11. 
TNF blockade with infliximab is recommended for cases that are 
serious or are refractory to steroids11—with the exception of patients 
with hepatitis, because of the putative role of TNF in promoting liver 
regeneration12. In this study, we provide evidence that the prophylactic 
blockade of TNF before the start of dual anti-CTLA-4 and anti-PD-1 
therapy prevents autoimmune adverse events in mouse models, and 
also enhances to some extent the anti-tumour efficacy of the combined 
treatment.
Colitis is among the most frequent and problematic immune- 
mediated adverse events that are associated with dual checkpoint 
inhibition11. Inflammatory bowel disease can be modelled in mice by 
providing dextran sulfate sodium (DSS) in the drinking water13,14. We 
performed a series of experiments in which a combination of anti-
CTLA-4 and anti-PD-1 monoclonal antibodies (Fig. 1a) was adminis-
tered to mice receiving DSS. The combination treatment exacerbated 
the autoimmune colitis syndrome induced by DSS and resulted in 
weight loss (Fig. 1b), a thickening of the wall of the large intestine (as 
detected by ultrasound; Fig. 1c, d) and worsening of colon inflamma-
tion (as assessed by histological techniques; Fig. 1e). TNF blockade 
is a recommended treatment for ulcerative colitis15 and Crohn’s 
disease. Prophylactic administration of the monoclonal antibody anti-
mouse TNF or the TNF inhibitor etanercept (TNFR2–IgG)16 clearly 
ameliorated the treatment-induced worsening of DSS-induced colitis 
(Fig. 1a–d).
We next studied whether prophylactic TNF blockade would affect 
the anti-tumour activity of the anti-PD-1 and anti-CTLA-4 combi-
nation in mice with established MC38 or B16-ovalbumin (OVA)-
derived tumours. Inhibition of TNF with a specific monoclonal 
antibody or etanercept did not impair the anti-tumour effects of dual 
checkpoint inhibition against MC38-derived tumours (Fig. 2a–c), 
and similar observations were made for B16-OVA-derived melano-
mas (Extended Data Fig. 1). These data indicate that TNF functions 
are dispensable and, to some extent, harmful to the anti-tumour 
activities of the combined immunotherapy regimens. In parallel 
experiments, we also attempted preventive blockade of IL-6, as previ-
ous reports suggested that neutralization of IL-6 could be a potential 
cancer treatment17,18. However, in our case, anti-tumour efficacy was 
partially reduced in the MC38 and B16-OVA models (Extended Data 
Fig. 2). Notably, the TNF-neutralizing agents resulted in a higher 
fraction of mice that completely rejected their tumour grafts, as 
compared with mice that were also treated with double checkpoint 
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inhibition but without prophylactic TNF blockade (Fig. 2). These 
data may be in line with a previous study, which reported that 
tumour-bearing mice that were either genetically deficient in TNF 
or subjected to TNF blockade responded slightly better to anti-PD-1 
single-agent treatment19.
We next sought to determine whether the enhancement of anti- 
tumour effects would also occur in MC38 tumour-bearing mice in 
which colitis had been concomitantly induced by DSS. Mice that 
received etanercept or anti-TNF monoclonal antibody in addi-
tion to double checkpoint blockade had an advantage in tumour 
rejection and survival over mice that received double checkpoint 
blockade alone (Fig. 2d–f). The neutralizing antibody was more 
consistently effective than etanercept, possibly owing to the fact 
that immune-competent mice develop anti-drug antibodies more 
efficiently in response to etanercept than to the anti-TNF antibody 
(Extended Data Fig. 3). In addition, combined anti-CTLA-4 and 
anti-PD-1 treatment increased TNF concentrations in the tumour 
microenvironment, but TNF was undetectable in serum samples from 
the same mice (Extended Data Fig. 4), and perhaps for this reason 
the better tissue penetration of the anti-TNF monoclonal antibody 
is preferable to that of etanercept.
Double checkpoint inhibition in mice with MC38 or B16-OVA 
tumours led to an increase in CD8+ T cells in the tumour infiltrate, 
and this was further enhanced by anti-TNF or etanercept treatment 
(Extended Data Fig. 5a). A similar increase was evident for tumour 
antigen-specific CD8+ T cells in the tumour microenvironment and 
tumour-draining lymph nodes, as detected by immunostaining with 
gp70 H-2Kb pentamer (Fig. 3a, b).
We investigated whether the beneficial anti-tumour effects of 
prophylactic TNF blockade could be related to the reversion of an 
exhaustion phenotype of CD8+ T cells. MC38 tumour-infiltrating 
CD8+ T cells that were subjected to double checkpoint blockade 
and TNF inhibition with either a neutralizing monoclonal antibody 
or etanercept had a lower surface expression of PD-1 (Extended 
Data Fig. 5b, d), as assessed by a non-competing anti-PD-1 mon-
oclonal antibody20. We also looked specifically at surface TIM3 
expression on tumour-specific tumour-infiltrating CD8+ T cells, as a 
result of a previous report19 in which TNF blockade led to a decrease 
in TIM3 expression after anti-PD-1 single-agent treatment—the 
enhanced efficacy of the anti-PD-1 treatment in combination with 
TNF blockade was attributed to this decrease. By contrast, in our 
study, the surface expression of TIM3 was not modified by dou-
ble checkpoint blockade either alone or in combination with TNF 
blockade (Extended Data Fig. 5c). We also tested a wide panel of 
molecules that are associated with T-cell exhaustion, and found 
no discernible changes—other than the reduction in PD-1—that 
could be attributed to the TNF blockade (Extended Data Fig. 6). 
The reduction in surface PD-1 did not result from internalization20; 
instead, it probably involved the selective expansion, on treatment, 
of CD8+ T cells that express little or no PD-1, as has been recently 
reported21,22.
Another mechanistic possibility for the enhanced anti-tumour 
effects is the attenuation of activation-induced cell death (AICD) in 
T lymphocytes23. Indeed, mouse T cells that are deficient in TNFR1 
(Tnfrsf1a−/−) reportedly undergo considerably higher levels of 
AICD24. In keeping with this finding, we observed that TNF blockade 
with anti-TNF or etanercept decreased apoptosis in T cell-receptor 
(TCR)-transgenic mouse CD8+ OT-I and Pmel-1 cells activated 
in culture with their respective cognate peptides in the presence 
of anti-PD-1 and anti-CTLA-4 monoclonal antibodies (Fig. 3c, d). 
Furthermore, in mice bearing MC38 tumours and suffering from 
DSS-induced colitis that were treated with double checkpoint block-
ade, systemic neutralization of TNF resulted in increased viability 
of tumour-reactive CD8+ T cells in the tumour microenvironment 
(Fig. 3e) and even more prominently so in tumour-draining lymph 
nodes (Fig. 3f). Notably, human CD8+ T lymphocytes—from healthy 
donors—that were activated with anti-CD3 and anti-CD28 monoclo-
nal antibodies underwent less AICD when cultured in the presence of 
infliximab (an anti-TNF monoclonal antibody) or etanercept (Fig. 3g, 
Extended Data Fig. 7).
To address the clinical applicability of these mouse data, we inves-
tigated whether the TNF pathway is turned on in patients with cancer 
who developed colitis upon checkpoint blockade. We analysed the 
mRNA expression of immune-related genes in sections of healthy 
mucosal tissue from colon biopsies of patients who either had 
checkpoint-induced colitis or had been diagnosed with bona fide 
ulcerative colitis (Fig. 4a, b). In all four cases of checkpoint-induced 
colitis that we tested, TNF mRNA expression was augmented, 
although it did not reach the level found in naturally occurring 
inflammatory bowel disease (Fig. 4a). The gene expression analyses 
were also consistent with transcripts reflecting local activation of the 
TNF gene signature (Fig. 4b). As TNF can be effectively targeted in 
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Fig. 1 | DSS-induced colitis, exacerbated by anti-PD-1 and anti-
CTLA-4, is ameliorated by prophylactic TNF blockade. a, Mice with 
DSS-induced colitis were treated intraperitoneally (i.p.) with anti-PD-1 
and anti-CTLA-4 monoclonal antibodies, either in combination with  
TNF blockade (using anti-TNF monoclonal antibodies or etanercept)  
or without TNF blockade. b, Normalized follow-up of body weight  
as a surrogate indicator of colitis severity in mice. Data are mean ± s.d. 
n = 9 biologically independent mice. P value was calculated using an  
extra sum-of-squares F test. ICB, immune checkpoint blockade.  
c, d, Representative ultrasound assessments (c) and quantification (d)  
of intestinal wall thickness. Red bars in c indicate wall thickness.  
L, quantification of intestinal wall thickness. Data are mean ± s.d. n = 8 
biologically independent mice for DSS and DSS + ICB; n = 3 for the 
groups treated with anti-TNF or etanercept. P value was calculated  
using a one-way analysis of variance (ANOVA) followed by Dunnett’s test.  
e, Quantification of the severity of colon wall inflammation in 
haemotoxylin and eosin (H&E)-stained sections. Histological grade was 
evaluated by a clinical pathologist blinded to the origin of samples. Data 
are mean ± s.d. n = 7 biologically independent mice for the groups treated 
with anti-TNF or etanercept; n = 6 for the other groups. P values were 
calculated using a one-way ANOVA followed by Dunnett’s test. Data are 
pooled from two independent experiments.
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ulcerative colitis, it makes sense that blocking this cytokine could 
also prevent or attenuate double checkpoint-induced colitis, given 
that TNF is upregulated in situ in the intestinal lesions of patients 
with this condition.
To further explore the applicability of our findings, we used a xeno-
graft-versus-host model of disease, in which human peripheral blood 
mononuclear cells (PBMCs) were infused into Rag2−/−Il2rg−/− mice. 
This condition causes the inflammation of several target organs, 
including the colon25. Treating these mice with combined ipilimumab 
and nivolumab exacerbated the disease and resulted in reduced body 
weight compared with animals that were prophylactically co-treated 
with etarnercept (Extended Data Fig. 8a). In this setting of multi- 
organ autoimmunity exacerbated by double checkpoint blockade, 
etanercept—but not control human IgG—reduced inflammation 
in the large intestine (as assessed by ultrasound examinations of 
intestinal wall thickness; Extended Data Fig. 8b, c). We also subcu-
taneously xenografted HT29 colon cancer cells into our humanized 
mouse model (Fig. 4c), and observed that tumour progression was 
controlled to some extent by dual nivolumab and ipilimumab treat-
ment. Concomitant etanercept treatment did not diminish these ther-
apeutic effects (Fig. 4d). Moreover, xenograft-versus-host-induced 
hepatitis and colitis were markedly reduced in etanercept-treated mice 
(Fig. 4e–g).
TNF blockade is not new in the arena of cancer immunotherapy. 
A previous study26 led to two clinical trials that tested etanercept and 
infliximab for the treatment of ovarian27 and renal28 cancer, respec-
tively. Although the observed clinical activity in these trials was mod-
est and not sufficient to warrant further clinical research, there was 
no reported evidence of disease hyper-progression. This suggests that 
TNF inhibition may constitute a safe treatment option in patients with 
advanced cancer.
On the basis of these results, together with our previous work, 
we propose that a sufficiently statistically powered phase II clin-
ical trial should be conducted in which patients undergoing dual 
ipilimumab and nivolumab treatment are also administered an 
approved anti-TNF agent, prophylactically or concomitantly with 
the immunotherapy regimen. A phase I investigator-initiated trial 
testing the safety of this combined approach is currently in progress 
(https://clinicaltrials.gov; NCT03293784), and we suggest that this 
should be followed by a larger clinical trial that examines both safety 
(measured as the percentage of immune-related adverse events that 
are of grade 2 or higher) and objective activity (measured as the 
percentage of overall response rate in patients). Our results indicate 
that an anti-TNF agent may— at least in the gut and in the liver— 
improve the safety of combined ipilimumab and nivolumab immu-
notherapy, as well as equalling or perhaps enhancing its efficacy. If 
this hypothesis is correct, prophylactic TNF blockade might allow 
doses of ipilimumab to be safely increased in combined immune 
checkpoint blockade regimens, thereby potentially strengthening 
their anti-tumour effects.
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Fig. 2 | Prophylactic TNF blockade does not hinder—and even 
enhances—the anti-tumour activity of combined anti-PD-1 and 
anti-CTLA-4 immunotherapy. a, Schematic representation of the 
treatments applied to mice that were subcutaneously (s.c.) engrafted 
with MC38 colon carcinoma cells. b, Overall survival of the indicated 
treatment groups. The numbers of biologically independent mice are 
indicated in c. P values were calculated using a two-sided log-rank 
test. c, Individual follow-up of mean tumour diameters, depicting the 
fraction of mice that completely rejected established tumours.  
d, Schematic representation of experiments performed as in a, but 
with colitis induced from day 9 by providing DSS in the drinking 
water. e, f, As b, c but for mice with DSS-induced colitis. The numbers 
of biologically independent mice are indicated in f. P values were 
calculated using a two-sided log-rank test. Data are pooled from three 
independent experiments.


























































































































































































































































































































































































































Fig. 3 | TNF blockade increases the infiltration of tumour-specific  
T cells in MC38-derived tumours and decreases AICD in CD8+  
T cells from mice and humans. Mice bearing MC38 tumours were 
treated as in Fig. 2d and killed on day 16. a, Tumour-specific CD8+  
T cells in the tumour microenvironment. n = 9 biologically independent 
mice for DSS and DSS + ICB + anti-TNF; n = 7 for DSS + ICB and 
DSS + ICB + etanercept. b, Tumour-specific CD8+ T cells in the 
tumour draining lymph nodes (DLN). n = 9 for DSS and DSS + ICB; 
n = 10 for the groups treated with anti-TNF or etanercept. c, OT-I CD8+ 
T cells were activated with cognate SIINFEKL peptide (25 ng ml−1). 
Anti-PD-1 and anti-CTLA-4 monoclonal antibodies (6.6 μg ml−1) 
were added to the ICB-treated cultures, and simultaneously anti-TNF 
(8.3 μg ml−1) or etanercept (2.6 μg ml−1) were added to the indicated 
conditions. Cell death was monitored by Zombie Nir staining of  
T cells after 72 hours. n = 6 biologically independent samples.  
d, Experiments were performed as in c, but with Pmel-1 T cells that  
were activated with 500 ng ml−1 of cognate gp100 peptide. n = 6 
biologically independent samples of cells. Data are pooled from two 
independent experiments (a–d). e, f, Mice bearing MC38 tumours  
were treated as in a, and the fraction of viable gp70-reactive CD8+  
T cells was assessed by viability-dye exclusion in gated CD8+  
T cells from cell suspensions that were derived from either tumour-
infiltrating lymphocytes (e) or tumour draining lymph nodes (f). n = 5 
biologically independent mice for DSS and DSS + ICB + anti-TNF; 
n = 4 for DSS + ICB and DSS + ICB + etanercept. One representative 
experiment out of three is shown (e, f). Data are mean ± s.d; P values 
were calculated using a one-way ANOVA followed by Dunnett’s test 
(a–f). g, PBMCs from healthy donors were activated with plate-bound 
anti-CD3 and anti-CD28 antibodies for seven days in the presence 
or absence of infliximab (10 μg ml−1) or etanercept (4 μg ml−1). Cell 
death was monitored by annexin V staining of CD8+ T cells. Data are 
mean ± s.d. n = 15 healthy donors for anti-CD3/CD28 + etanercept; 
n = 11 for anti-CD3/CD28 + infliximab. P values were calculated using 
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Fig. 4 | TNF is involved in immune checkpoint blockade-induced 
colitis in patients and in a humanized mouse model. Gene-expression 
profiling (using an nCounter Analysis System with the PanCancer 
Immune Profiling Panel set of probes) was performed in different 
samples of human mucosal tissue from colon biopsies: four samples  
of healthy mucosal tissue from the large intestine (control); samples  
from four cases of colitis induced by immune checkpoint blockade  
(ICB-colitis); and samples from four cases of ulcerative colitis.  
a, Gene expression of TNF. Centre line, median; box limits, 25th to  
75th percentiles; whiskers, minimum and maximum values. n = 4 
biologically independent patient samples. P values were calculated using 
a one-way ANOVA followed by Dunnett’s test. b, Gene signature that 
denotes TNF activation in the ICB-colitis and ulcerative colitis groups 
versus the control group. Data are from a single experiment (a, b).  
c, Schematic representation of the treatments applied to immunodeficient 
Rag2−/−Il2rg−/− mice that were first subcutaneously engrafted with HT29 
colon carcinoma cells, followed by the infusion of human PBMCs after 
seven days. Mice were injected on days 7, 11, 14 and 17 intraperitoneally 
with combined ipilimumab and nivolumab, with or without etanercept 
(40 μg; given subcutaneously). As an antibody control, we used human 
polyclonal IgG. d, Mean tumour volumes. Data are mean ± s.d. n = 5 
biologically independent mice for IgG; n = 6 for treated groups.  
P values were calculated using an extra sum-of-squares F test. e, Alanine 
transaminase (ALT) and aspartate transaminase (AST) serum levels on 
day 24. f, Ultrasound assessments of intestinal wall thickness on day 24. 
Data are mean ± s.d. n = 5 for IgG; n = 6 for treated groups. P values 
were calculated using a one-way ANOVA followed by Dunnett’s test (e, f). 
g, Representative ultrasound images of the treatment groups described 
in f. Red bars indicate intestinal wall thickness. Data are from a single 
experiment.
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METHODS
Mice and cell lines. Female C57BL/6 mice (6 weeks old) were obtained from the 
Jackson Laboratory and maintained in the animal facility of Cima Universidad de 
Navarra. Rag2−/−Il2rg−/−, OT-I and Pmel-1 mice were bred and maintained in 
the animal facility of Cima Universidad de Navarra. Experimental protocols were 
approved by the Ethics Committee of the Universidad de Navarra and the Institute 
of Public Health of Navarra according to European Council Guidelines (protocol 
numbers 060-17 and 024-17). Sample size estimations were performed using G 
Power software. Mice were randomized at the beginning of each experiment and 
experiments were not blinded. Mice were killed when tumours reached a mean 
diameter of 20 mm diameter, and this limit was not exceeded in any of the exper-
iments. We complied with all ethical regulations. MC38 cells were a gift from K. 
E. Hellström (University of Washington) in September 1998. B16-OVA cells were 
provided by L. Chen (Yale University) in November 2001. These cell lines were 
authenticated by Idexx Radil (case 6592-2012) in February 2012. HT29 cells were 
obtained from ATCC. MC38, B16-OVA and HT29 cell lines were maintained at 
37 °C in 5% CO2 and were grown in RPMI medium (RPMI 1640) with Glutamax 
(Gibco; Invitrogen) containing 10% heat-inactivated fetal bovine serum (Gibco; 
Invitrogen), 100 IU ml−1 penicillin and 100 g ml−1 streptomycin (Biowhittaker). 
After seven to nine days in culture, cells were tested for mycoplasma contamination 
and 500,000 cells per mouse were injected subcutaneously. Tumour growth was 
monitored twice a week with an electronic caliper.
Treatments. Mice received 100 μg of anti-CTLA-4 antibody (InVivoMAb 
BioXCell; anti-mouse CTLA-4, clone 9D9) and 100 μg of anti-PD-1 antibody 
(InVivoMAb BioXCell; anti-mouse PD-1, clone RMP1-14) per injection intra-
peritoneally. Colitis treatment consisted of the intraperitoneal administration of 
anti-mouse TNF antibody (125 μg per injection per mouse; InVivoMAb BioXCell; 
clone XT3.11) as previously described29, or etanercept (40 μg per injection per 
mouse; Enbrel). Anti-mouse IL-6 antibody (InVivoMAb BioXCell; clone MPF5-
20F3) was administered intraperitoneally (250 μg per dose).
DSS-induced colitis. Mice were orally administered 3% DSS (36–50 kDa; MP 
Biomedicals) in their drinking water for three days to induce acute colitis. The 
experiments were performed in these conditions because a protocol reported pre-
viously30, which included 3% DSS in water over seven days, proved to be very toxic 
and produced high mortality in our model.
Colitis assessment. Several different parameters were used for colitis assessment. 
Mouse weight was monitored daily. Colon ultrasound scans were performed on 
days 0 and 7 using a Vevo 770 ultrasound system (Visualsonics) equipped with a 
real-time micro-visualization scanhead probe (RMV-710 B) working at a frame 
rate of 110–120 frames per second. The nosepiece transducer used had a central 
frequency of 25 MHz, a focal length of 15 mm and 70 mm of nominal spatial reso-
lution. Scans were performed by a trained technician and intestinal wall thickness 
was determined. For histological studies, paraffin-embedded colon sections (4 μm) 
from each animal were stained with H&E. Histological changes were graded as 
previously described31. In brief, histological scores were determined blindly, based 
on analysis of the inflammatory cell infiltrate and changes in intestinal architecture.
Inflammatory cell infiltrate scores were as follows: 0, regular infiltrate; 1, infil-
tration of the lamina propia; 2, cryptitis; 3, crypt abscesses, surface erosion or 
ulceration.
Intestinal architecture scores were as follows: 0, regular architecture; 1, irregular 
crypts or irregular villous surface; 2, crypt loss; 3, ulceration or granulation tissue.
Mouse lymphocyte survival study. For in vitro experiments, 1.5 × 106 splenocytes 
from 6–10-week-old male or female OT-I or Pmel-1 transgenic mice were isolated 
and activated with 25 ng ml−1 of SIINFEKL peptide (Invivogen) or 500 ng ml−1 
of gp100 peptide (GenScript), respectively. Splenocytes were also treated with 
6.6 μg ml−1 of anti-CTLA-4 plus 6.6 μg ml−1 of anti-PD-1, and 2.6 μg ml−1 of 
etanercept or 8.3 μg ml−1 of anti-TNF. After 72 h, survival was analysed by flow 
cytometry (BD FACSCanto II system; anti-CD8 BV510, clone 53-6.7 (Biolegend); 
anti-CD3 PeCy7, clone 17A2 (Biolegend); Zombie NIR (Biolegend)).
For in vivo experiments, MC38 tumours were implanted subcutaneously 
and treated as described above. Seven days after the start of treatment, tumours 
were removed and the survival of antigen-specific CD8+ cells was analysed by 
flow cytometry in tumours and draining lymph nodes (BD FACSCanto II sys-
tem; anti-CD8 BV510, clone 53-6.7 (Biolegend); anti-CD3 PeCy7, clone 17A2 
(Biolegend); Zombie NIR (Biolegend); H-2Kb KSPWFTTL R-Pe-labelled Pro5 
MHC Pentamer (ProImmune).
Human lymphocyte survival study. PBMCs from 21 healthy white donors 
(21–42 years old, males and females) were enriched using Ficoll-Paque Plus (GE 
Healthcare) and isolated by density-gradient centrifugation. All samples were 
obtained after consent from the healthy donors and Institutional Review Board 
approval from Clínica Universidad de Navarra, and we complied with all ethi-
cal regulations. PBMCs were stimulated with 0.5 μg ml−1 plate-bound anti-CD3 
(OKT-3; eBioscience) and 1 μg ml−1 anti-CD28 (CD28.2; eBioscience) in the pres-
ence or absence of 10 μg ml−1 infliximab or 4 μg ml−1 etanercept. All cultures were 
carried out in the presence of 20 IU ml−1 recombinant human IL-2 (Proleukin; 
Novartis) in RPMI-10% fetal bovine serum at 37 °C. Seven days later, cells were 
replated into fresh anti-CD3 and anti-CD28-coated plates and cultured overnight 
in the presence of all stimuli. Cells were analysed by multicolour flow cytome-
try (BD FACSCanto II system; Zombie NIR (Biolegend); anti-CD3 PeCy7, clone 
UCHT1 (BD Biosciences; anti-CD8 BV510, clone BC96 (Biolegend); CD4–APC, 
clone OKT4 (Biolegend); annexin V FITC (Biolegend)). All analysis was performed 
using FlowJo 10.4.2 software (Tree Star).
NanoString and nCounter technology. For TNF signature analysis, we selected 
four mucosal biopsies from patients without bowel inflammation, four from 
patients with spontaneous active ulcerative colitis that was not associated with 
immunotherapy and four from patients who had immunotherapy-induced colitis. 
Among the immunotherapy-induced colitis patients, two were male and two were 
female, and there were two cases of grade 4 colitis refractory to corticosteroids. 
Two of the immunotherapy-related colitis cases occurred after treatment with ipil-
imumab and two after combined ipilimumab and nivolumab treatment. Among 
the four patients with spontaneous active ulcerative colitis, three were male and 
one female (20–69 years old). In the group without bowel inflammation, patients 
had colorectal adenocarcinoma, were 61–86 years old, and two were male and two 
female. Sample anonymization was performed by the corresponding biobanks. 
All biopsies were obtained after consent from the patients and after Institutional 
Review Board approval from Clínica Universidad de Navarra, Hospital General 
Universitario Gregorio Marañon and Hospital Universitario Virgen de la Victoria, 
and we have complied with all ethical regulations. A pathologist selected the formalin- 
fixed paraffin-embedded (FFPE) tumour block with the greatest area of viable 
normal mucosa of colon or ulcerative colitis, and estimated the tumour cellularity 
(>10%) and the tumour surface area within the circled area of the H&E-stained 
slide (>4 mm2). FFPE samples were sent to the University of Málaga (CIMES) for 
macrodissection of material and RNA extraction using an RNA isolation kit and 
procedures provided by NanoString Technologies. The optical density of total RNA 
was measured at 260 nm and 280 nm to determine yield and purity. RNA samples 
were used if the measured concentration equalled or was higher than 12.5ng μl−1 
and the absorbance ratio (260 nm/280 nm) was 1.7–2.5. Gene-expression profiling 
was performed on an nCounter Analysis System using the PanCancer Immune 
Profiling Panel set of probes (770 genes: 730 cancer-related human genes and 40 
internal reference controls). The hybridization reaction was performed using a 
nominal RNA input of 250 ng. The hybridization time was 15–21 h, using a bench-
top thermocycler set to 65 °C with a heated lid set to 70 °C. The manufacturer's 
specifications were followed for the nCounter Prep Station, which prepares the 
hybridized products for imaging. The nCounter Digital Analyzer reports the digital 
counts that represent the number of molecules labelled with a fluorescent bar-
code for each probe-targeted transcript. Data were analysed using nSolver software 
(Nanostring Technologies) and Ingenuity Pathway Analysis (Ingenuity Systems).
Xenograft-induced colitis experiment. On day 0, 8–12-week-old female 
Rag2−/−Il2rg−/− mice were inoculated subcutaneously with 5 × 105 HT29 cells. 
On day 7 after tumour-cell inoculation, 107 human PBMCs resuspended in 1 ml 
PBS were injected intraperitoneally. Human blood samples were obtained from 
healthy donors, and fresh PBMCs were isolated by density-gradient separation 
(Ficoll Paque Plus; GE Healthcare).
On days 7, 11, 14 and 17, mice were injected intraperitoneally with ipilimumab 
(200 μg) and nivolumab (200 μg), and subcutaneously with etanercept (40 μg). 
As an antibody control, we used human IgG (200 μg). Ultrasound analyses of the 
intestine were performed on day 24, and photographs were obtained. Mice were 
bled on day 24 for serum collection. Transaminase analyses were performed on 
the Roche Cobas platform. Xenografted tumours were measured every three days.
Anti-drug antibody assay. MC38 tumour-bearing mice were treated with DSS 
with or without anti-TNF or etanercept. Serum samples were collected on days 
4 and 8 after the beginning of treatment, and the samples were stored at −20 °C 
until analysis for anti-drug antibodies by an enzyme-linked immunosorbent assay 
(ELISA). In brief, 1:5 serially diluted serum samples, starting from a 1:10 dilution, 
were added to 96-well plates that were pre-coated with 0.1 μg in 50 μl of rat anti-
TNF or etanercept, for the individual detection of anti-drug antibodies in serum 
from mice treated with DSS + ICB + anti-TNF or DSS + ICB + etanercept, respec-
tively. As negative controls, sera collected from mice that were only treated with 
DSS were used. As a positive control, wells pre-coated in purified mouse IgG were 
used. To allow binding between the immobilized antibody and anti-drug antibod-
ies, samples were incubated for 1.5 h at 37 °C, followed by thorough washing with 
PBS TWEEN 0.05% buffer (PBST) to eliminate unbound samples. Next, a highly 
cross-absorbed horseradish peroxidase (HRP)-labelled goat anti-mouse IgG (Life 
Technologies) was added at a 1:8,000 dilution and the samples were incubated 
for 1.5 h at 37 °C, followed by a thorough wash with PBST. HRP was detected by 
incubation with 3,3′,5,5′-tetramethylbenzidine substrate reagent (BD Biosciences) 
as per the manufacturer’s instructions. The colorimetric reaction was measured 
in a spectrophotometer (λ = 450 nm). Data were represented by normalizing the 
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absorbance data from serum samples to the absorbance data obtained from the 
positive control. Half-maximal effective concentration (EC50) values were calcu-
lated by a sigmoidal regression model.
TNF detection. To determine the levels of TNF protein in the tumour microenvi-
ronment, the tumour was first homogenized by mechanic disruption with a pestle 
in PBS buffer with complete protease inhibitors. After centrifugation, the super-
natant was collected and stored at −20 °C for further use. Circulating TNF was 
measured in serum samples. 1:10 dilutions of tumour supernatant or 1:2 dilutions 
of serum were used to evaluate the levels of TNF protein, using the Mouse TNF 
ELISA Set II kit (BD OptEIATM) as per the manufacturer’s instructions. The col-
orimetric reaction was measured in a spectrophotometer (λ = 450 nm).
List of antibodies used as T cell exhaustion-related markers. Anti-mouse eomes-
odermin (clone Dan11mag) eFluor 660, anti-mouse TIM3 (clone B8.2C12) PE/
Dazzle 594, anti-human/mouse Tbet (clone eBio4B10) PECy7, anti-mouse CD45 
(clone 30-F11) BV510, anti-mouse TCRβ (clone H57-597) BV610, anti-mouse 
CD19 (clone 6D5) BV660, anti-mouse CD8 (clone 53-6.7) BUV395, anti-mouse 
CD4 (clone GK1.5) BV496, anti-mouse FOXP3 (clone MF-14) BV421, anti-mouse 
Ki67 (clone 188A) Alexa Fluor 700, anti-mouse PD-1 (clone 29F.1A12), anti-mouse 
CTLA-4 (clone 1B8) FITC, anti-mouse LAG3 (clone C9B7W) PerCP-eFluor 510, 
anti-mouse 2B4 (clone m2B4-B6-4558.1) FITC, anti-mouse BTLA (clone 6F7) 
PerCP-eFluor 510, anti-mouse CD160 (clone CNX46-3) BV421, gp70 pentamer–
PE, gp100 (KVPRNQDWL) pentamer–APC and OVA SIINFEKL) tetramer–PE. 
Stained cell suspensions were analysed by multicolour flow cytometry (Cytoflex, 
Beckman Coulter).
Statistical analysis. Prism software (GraphPad Software) was used for statistical 
analysis. We used the log-rank test to determine the significance of differences in 
survival curves. Mean differences were compared using t-tests (for comparisons of 
two groups) or one-way ANOVA followed by multiple-comparison tests (for com-
parisons of three of more groups). Longitudinal data were fitted to a third-order 
polynomial equation and compared with an extra sum-of-squares F test. P values 
<0.05 were considered to be statistically significant.
Reporting summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this paper.
Data availability
Source Data for all figures are provided.
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Extended Data Fig. 1 | Anti-tumour activity of double immune 
checkpoint blockade on B16-OVA-derived tumours on TNF blockade. 
a, Schematic representation of experiments. Experiments were performed 
as in Fig. 2a, but on mice bearing B16-OVA-derived tumours, treated in 
different groups. b, Overall survival of treatment groups. The numbers of 
biologically independent mice are indicated in c. P values were calculated 
using a two-sided log-rank test. c, Individual follow-up of tumour size, 
depicting the fraction of mice that completely rejected their tumours.  
One representative experiment out of two is shown.
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Extended Data Fig. 2 | Prophylactic IL-6 blockade hinders the 
anti-tumour activity of the combined anti-PD-1 and anti-CTLA-4 
immunotherapy regimen. a, Schematic representation of the treatments 
applied to mice that were subcutaneously engrafted with MC38 colon 
carcinoma cells (the results from these mice are presented in b).  
b, Individual follow-up of tumour mean diameters, depicting the fraction 
of mice that completely rejected established tumours. c, Schematic 
representation of the treatments applied to mice that were subcutaneously 
engrafted with B16-OVA melanoma cells (the results from these mice are 
presented in d). d, Individual follow-up of tumour size, as in b. Data are 
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Extended Data Fig. 3 | Administration of etanercept causes mice to 
develop anti-drug antibodies. An assay to detect anti-drug antibodies  
was performed on serum that was collected from MC38 tumour-bearing 
mice 4 or 8 days after the start of treatment with TNF blockade (as in 
Fig. 2d). a, c, Percentages of normalized absorbance. Percentages reflect 
the levels of antibody against rat anti-TNF or anti-etanercept, as measured 
by ELISA on day 4 (a) and day 8 (c). b, d, EC50 values for day 4 (b) and  
day 8 (d). Data are mean ± s.d. n = 15 biologically independent 
mice for DSS, n = 13 for DSS + ICB + anti-TNF and n = 9 for 
DSS + ICB + etanercept. P values were calculated using a one-way 
ANOVA followed by Dunnett’s test. A sigmoidal dose–response equation 
was used to determine EC50. The continuous line represents the nonlinear 
regression curve fit, and the dotted line represents the s.d. Data are pooled 
























Extended Data Fig. 4 | Increased concentrations of TNF in the tumour 
microenvironment after immune checkpoint blockade therapy. Tumour 
homogenates were prepared from mice 24 h after they finished the 
treatment regimen described in Fig. 2d. Levels of TNF in the tumour are 
shown. Data are mean ± s.d. n = 4 biologically independent mice. P values 
were calculated using a two-sided t-test. TNF was undetectable in serum 




















































































































































































































































































































Extended Data Fig. 5 | Downregulation of PD-1 expression on 
tumour-infiltrating antigen-specific CD8+ T cells following the 
combined anti-PD-1 and anti-CTLA-4 immunotherapy regimen. 
Tumours from MC38 and B16-OVA mouse models were collected 24 h 
after the mice finished the treatment regimen described in Fig. 2d, and 
cell suspensions were analysed by flow cytometry. a, The percentage of 
total TCRβ+CD8+ T cells among viable CD45+ cells for MC38 (top) 
and B16-OVA (bottom) tumours. b, Median fluorescence intensity 
(MFI) of surface PD-1 for PD-1+ cells previously gated on viable 
CD45+CD19−TCRβ+CD8+ gp70 pentamer+ cells (top) or OVA tetramer+ 
cells (bottom). c, MFI of surface TIM3 for TIM3+ cells previously gated 
on viable CD45+CD19−TCRβ+CD8+gp70 pentamer+ cells (top) or 
CD45+CD19−TCRβ+CD8+OVA tetramer+ cells (bottom). Data are 
mean ± s.d. For the MC38 models (top), n = 7 biologically independent 
mice for DSS and DSS + ICB and n = 6 for the groups treated with 
anti-TNF or etanercept; for the B16-OVA models (bottom), n = 6 for 
DSS + ICB+ anti-TNF and n = 10 for the other groups. P values were 
calculated using a one-way ANOVA followed by Dunnett’s test, and each 
condition was compared with the DSS group as a control. d, Representative 
contour plots of PD-1 and TIM3 in the experimental groups described in b 
for viable CD45+CD19−TCRβ+CD8+gp70 pentamer+ cells. Fluorescence 









































































































































































































































































































































































































































Extended Data Fig. 6 | Expression of T cell exhaustion-related markers 
on T cells following immune checkpoint blockade treatment with or 
without TNF blockade. a–f, Tumour-specific CD8+ T cells recognizing 
gp70 (top) or OVA (bottom), in tumour-cell suspensions that were derived 
one day after completion of the indicated treatments, were analysed by 
multicolour flow cytometry. Expression of surface CTLA-4 (a), LAG3 (b), 
BTLA (c), 2B4 (d), CD160 (e) and intracellular Ki67 (f) are shown. Data 
are MFI (mean ± s.d.) for surface markers (a–e) and percentage of positive 
cells (mean ± s.d.) for Ki67 (f). For the MC38 models (top), n = 3; for 
the B16-OVA models (bottom), n = 4 for the DSS + ICB group and n = 5 
for the other groups. P values were calculated using a one-way ANOVA 
followed by Dunnett’s test, and each condition was compared with the 













































































































Extended Data Fig. 7 | Gating strategy and representative contour  
plots of AICD protection by TNF blockade in human PBMCs.  
a, Gating strategy for flow cytometry analysis. b, Representative contour 
plots showing annexin V-positive cells among CD8+ T lymphocytes 
after stimulation with anti-CD3 and anti-CD28, with or without TNF 




























































Extended Data Fig. 8 | The TNF axis is involved in immune-mediated 
colitis, as exacerbated by immune checkpoint blockade, in immune-
deficient mice reconstituted with human PBMCs. Fresh human 
PBMCs were injected intraperitoneally on day 0 into immunodeficient 
Rag2−/−Il2rg−/− mice. On days 0, 4, 7 and 10, mice were injected 
intraperitoneally with ipilimumab (200 μg) and nivolumab (200 μg), 
with or without etanercept (40 μg; given subcutaneously). As an antibody 
control, we used human polyclonal IgG. a, Normalized follow-up of body 
weight. Data are mean ± s.d. n = 4 biologically independent mice for 
all groups, except n = 5 for PBMCs + ICB + etanercept. P values were 
calculated using an extra sum-of-squares F test. b, Ultrasound assessments 
of intestinal wall thickness. Data are mean ± s.d. n = 4 biologically 
independent mice for PBMCs + IgG, n = 3 for PBMCs + ICB and n = 5 
for PBMCs + ICB + etanercept. P values were calculated using a one-way 
ANOVA followed by Dunnett’s-test. c, Representative ultrasound images 
estimating colon wall thickness in the different experimental groups 
described in b. Red bars indicate intestinal wall thickness. Data are from a 
single experiment.
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For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Clearly defined error bars 
State explicitly what error bars represent (e.g. SD, SE, CI)
Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection GraphPad Prism® 7.01 (GraphPad Software, Inc., La Jolla, CA), Microsoft Excel 2010
Data analysis GraphPad Prism® 7.01 (GraphPad Software, Inc., La Jolla, CA), nSolver 4.0 software (Nanostring Technologies, Seattle, WA), FlowJo 10.4.2 
software (Tree Star, San Carlos, CA) and Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City, CA).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers 
upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
All figures have associated raw data.
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Please select the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences Behavioural & social sciences  Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/authors/policies/ReportingSummary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size To calculate the sample size we used the computer application G Power software (http://www.gpower.hhu.de/).
Data exclusions None
Replication All studies have been repeated at least twice with similar results except experiments in Rag2-/-IL2Rγnull mice  (that were performed with and 
without tumors) and NanoString data.
Randomization The animals were randomly assigned to the groups.
Blinding This manuscript focused on preclinical research. Assays were not blinded because the administration and sample collection and processing 
carried out by 
the same researchers.
Reporting for specific materials, systems and methods
Materials & experimental systems





Animals and other organisms
Human research participants
Methods





Antibodies used Anti-CTLA-4 antibody (InVivoMAb BioXCell anti-mouse CTLA-4, Clone 9D9), anti-PD-1 antibody (InVivoMab BioXCell anti-mouse 
PD-1, Clone RMP1-14), anti-mouse TNF-α antibody (InVivoMAb BioXCell, Clone XT3.11, eBioscience, San Diego, CA),  Etanercept 
(Enbrel®), anti-CD8 BV510 clone 53-6.7 Biolegend, anti- CD3 PeCy7 clone 17A2 Biolegend, R-Pe Labelled Pro5 MHC Pentamer 
ProImmune, anti-PD-1 FITC clone 29F.1A12 Biolegend, anti-TIM-3 PerCP/Cy5.5 clone RMT3-23 Biolegend.
Validation All antibodies were commercially available and validation can be found in the respective webpage.
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) MC38 cells were a kind gift from Dr. Karl E. Hellström (University of Washington, Seattle, WA) in September 1998. B16-OVA 
cells were provided by Dr. Lieping Chen (Yale University, New Haven, CT) in November 2001. HT29 were obtained from ATCC.  
Authentication MC38 and B16-OVA cell lines were authenticated by Idexx Radil (Case 6592-2012) in February 2012.
Mycoplasma contamination All cell lines were tested negative for mycoplasma contamination.
Commonly misidentified lines
(See ICLAC register)
We did not used commonly misidentified lines.
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Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals 6 week-old female C57BL/6 mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and maintained in the animal 
facility of the Cima Universidad de Navarra.  6-10 week-old male or female OT-I transgenic mice,  6-10 week-old male or female 
Pmel-1  transgenic mice and 8-12 week-old female Rag2-/-IL2Rγnull were bred and maintained in the animal facility of Cima 
Universidad de Navarra. Experimental protocols were approved by the Ethics Committee of the University of Navarra and the 
Institute of Public Health of Navarra according to European Council Guidelines (protocol numbers: 060-17 and 024-17).
Wild animals The study did not involve wild animals.
Field-collected samples The study did not involve samples collected from the field.
Human research participants
Policy information about studies involving human research participants
Population characteristics For TNF signature analysis, we selected four mucosal biopsies from patients without bowel inflammation, four from patients with 
spontaneous active ulcerative colitis that was not associated with immunotherapy and four from patients who had 
immunotherapy-induced colitis. Among the immunotherapy-induced colitis patients, two patients were male and two were 
female, and there were two cases of grade 4 colitis refractory to corticosteroids. Two of the immunotherapy-related colitis cases 
occurred after treatment with ipilimumab and two after combined ipilimumab and nivolumab treatment. Among the four 
patients with spontaneous active ulcerative colitis, three were male and one female (20–69 years old). In the group without 
bowel inflammation, patients had colorectal adenocarcinoma, were 61–86 years old, and two were male and two female. 
Sample anonymization was performed by the corresponding biobanks. All biopsies were obtained after consent from the 
patients and Institutional Review Board approval from Clínica Universidad de Navarra, Hospital General Universitario Gregorio 
Marañon and Hospital Universitario Virgen de la Victoria. PBMCs were obtained from 21 healthy white donors (21-42 years, 
males and females) were enriched using Ficoll-Paque Plus (GE Healthcare, Menlo Park, CA) and isolated by density gradient 
centrifugation. All samples were obtained after consent from the healthy donors and Institutional Review Board approval from 
Clínica Universidad de Navarra and we have complied with all ethical regulations. 
Recruitment A pathologist selected the FFPE tumor block with the greatest area of viable normal mucosa of colon or ulcerative colitis and 




The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation Spleens, draining lymph nodes or tumors were mechanically dissociated. Tumor suspensions were treated with DNAse and 
collagenase.
Instrument FACSCanto™ II (Beckman Coulter) and Cytoflex (Beckman Coulter)
Software FlowJo 10.4.2 (Tree Star, Ashland, OR)
Cell population abundance N.A.
Gating strategy N.A.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
